Produits laitiers : Le lait et le fromage sont galement de bonnes sources de carnitine
24% overall reduction in symptom severity from baseline in the test group
Lillys eloralintide (amylin receptor agonist), providing a potential option for Lilly to defend against amylin analogues, including Novo Nordisks CagriSema, which combines dual amylin and calcitonin receptor agonist cagrilintide and semaglutide, or Zealands petrelintide (phase 2) Structure Therapeutics GSBR-1290 (GLP-1), small molecule, oral obesity therapy, seeking to substantiate its earlier, positive phase 2a data to deliver competitive weight loss, against both other oral therapies and marketed injectables, with acceptable tolerability (phase 2b) Crucially, a number of phase 3 readouts in 2025 for key AOM assets will set the stage for their launch in 2026, when the next wave of AOMs enter the market to re-shape the competitive landscape: Lillys orforglipron (GLP-1), one of the first oral AOMs to launch, possibly alongside oral semaglutide, and when it does, the first small molecule based therapy in the market

People in their later years are more likely to develop heart problems such as arteriosclerosis and coronary artery disease
Products formulated for better absorption may be more effective
First, the FDAs resolution of the semaglutide and tirzepatide shortages in mid-2024 ended the broad compounding allowance under section 503A, narrowing the legal path for compounded versions to patients with documented medical need (specific dose unavailable, sensitivity to a commercial inactive ingredient)